Le Lézard
Classified in: Health
Subjects: SVY, MAT

Cannabis Prohibition Linked to 90% More Delta 8 THC Searches, According to CBD Nationwide's Latest Research


Study of Nationwide Trends Discovers a Direct Correlation Between Cannabis Bans and Increased Searches for Delta 8 and Delta 9 THC.

SAN DIEGO, Feb. 8, 2024 /PRNewswire/ -- CBD Nationwide's latest study reveals a 90% spike in Delta 8 THC searches in states banning recreational cannabis, highlighting the significant influence of legal status on cannabinoid interest.

"Cannabis prohibition clearly doesn't work" says Katie Devoe, CEO of CBD Nationwide, the company that published the research.

Utilizing Google Trends data, this concise analysis not only showcases the direct correlation between cannabis legislation and increased Delta 8 and Delta 9 THC interest but also marks a crucial step in understanding how legal frameworks shape public curiosity. The data encourages important questions about the impact of cannabis legislation on public behavior.

Delta 8 THC Searches Surge: States banning recreational cannabis see a 90% increase in searches for Delta 8 THC, indicating a clear shift towards alternative cannabinoids.

Delta 9 THC Demand Rises: Legislation-driven bans boost Delta 9 THC search interest by 27%, broadening the cannabinoid exploration landscape.

Accesible Cannabis Alternatives: Delta 8 and Delta 9 THC, quasi-legal cannabinoids available online, offer alternatives to traditional cannabis in areas facing restrictions.

Proven Correlation: Analysis confirms the link between cannabis bans and rising Delta 8 and Delta 9 THC interest is statistically solid, with a less than 1 in 1 million chance of being random.

Market and Policy Implications: The surge in searches for alternative cannabinoids, driven by cannabis bans, underscores the limitations of prohibition and highlights emerging market opportunities alongside the need for nuanced policy-making.

Complete Study Results: https://cbdnationwide.com/cannabis-bans-shaping-online-trends/

CBD Nationwide, a B2B leader in the cannabis and nutritional supplement sector, blends over ten years of scientific expertise, legal compliance, and premier production to drive industry innovation.

Contact

Katie Devoe CEO
CBD Nationwide
(844) 442-2369
[email protected] 
https://cbdnationwide.com

SOURCE CBD Nationwide


These press releases may also interest you

at 00:01
ZYMFENTRAtm (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis
Celltrion USA announced today...

at 00:01
New Peer-Reviewed Clinical Studies Show SonarMD Reduces Emergency Department Visits and Hospitalizations for Patients with Ulcerative Colitis and Crohn's Disease
SonarMD today presented positive results from two large, longitudinal studies evaluating several major drivers of medical costs in people living with Inflammatory Bowel Disease (IBD) ? defined as people living with ulcerative colitis or Crohn's...

at 00:00
Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that it signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA) to begin discussions on the creation of an innovative cell therapy...

20 mai 2024
Dental Tourism | The Best Dentists Option in Tijuana Mexico - Smile 4 Ever Mexico
Joel's journey to Smile 4 Ever Mexico in Tijuana exemplifies the transformative power of affordable dental care. Struggling with dental problems that affected his quality of life, Joel found a solution in Tijuana, where dental procedures are...

20 mai 2024
ILJIN SNT Co., Ltd. Calls for Board Restructure at Aurinia Pharmaceuticals
Fellow Aurinia Shareholders, ILJIN SNT Co., Ltd. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company") and has been supportive of the Company's mission since 2010...

20 mai 2024
Innovent Announces the New Drug Application of IBI311 (IGF-1R antibody) has been Accepted by the NMPA of China for Thyroid Eye Disease
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major...

More news about Health...


News published on and distributed by: